Puma Biotechnology, Inc. (PBYI)
| Market Cap | 365.46M +142.2% |
| Revenue (ttm) | 227.18M -2.4% |
| Net Income | 24.38M -35.9% |
| EPS | 0.48 -38.1% |
| Shares Out | 50.90M |
| PE Ratio | 15.01 |
| Forward PE | 26.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,165 |
| Open | 7.23 |
| Previous Close | 7.24 |
| Day's Range | 7.08 - 7.23 |
| 52-Week Range | 3.03 - 7.90 |
| Beta | 1.23 |
| Analysts | Hold |
| Price Target | 5.00 (-30.36%) |
| Earnings Date | May 7, 2026 |
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breas... [Read more]
Financial Performance
In 2025, Puma Biotechnology's revenue was $228.37 million, a decrease of -0.91% compared to the previous year's $230.47 million. Earnings were $31.11 million, an increase of 2.75%.
Financial StatementsAnalyst Summary
According to one analyst, the rating for PBYI stock is "Hold" and the 12-month stock price target is $5.0.
News
Puma Biotechnology Q1 Earnings Call Highlights
Puma Biotechnology NASDAQ: PBYI reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million, accord...
Puma Biotechnology reports Q1 adjusted EPS (4c) vs (10c) last year
Reports Q1 revenue $44.8M vs $42M last year. “We are very pleased that the first quarter of 2026 marked another quarter of year-over-year demand increase resulting in our raising revenue…
Puma Biotechnology sees Q2 revenue $52M-$55M, one estimate $52M
16:58 EDT Puma Biotechnology (PBYI) sees Q2 revenue $52M-$55M, one estimate $52M
Puma Biotechnology raises FY26 revenue view to $222M-$229M from $214M-$221M
One estimate $218M.
Puma Biotechnology Earnings Call Transcript: Q1 2026
Q1 2026 saw NERLYNX revenue decline sequentially due to inventory drawdown, but new patient starts rose 25% and the company is now debt-free. Updated guidance raises FY 2026 revenue and net income expectations, with strong clinical progress in biomarker-driven trials.
Puma Biotechnology Earnings release: Q1 2026
Puma Biotechnology released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Puma Biotechnology Quarterly report: Q1 2026
Puma Biotechnology has published its Q1 2026 quarterly earnings report on May 7, 2026.
Puma Biotechnology Slides: Q1 2026
Puma Biotechnology has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Puma Biotechnology Reports First Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology hosted a conference call and provided a corporate update on May 7, 2026, following release of its 1Q-2026 financial results.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted to six new hires in April 2026, as required under Nasdaq Listing Rule 5635(c)(4) .
Puma Biotechnology Proxy statement: Proxy filing
Puma Biotechnology filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Puma Biotechnology Proxy statement: Proxy filing
Puma Biotechnology filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call on May 7 at 1:30 p.m. PT, following release of its first quarter 2026 financial results.
Puma Biotechnology Proxy statement: Proxy filing
Puma Biotechnology filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Puma Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference
NERLYNX continues to show strong commercial growth, with increasing revenues and improved patient tolerability. Alisertib advances in phase II trials for breast and lung cancers, with interim and full data readouts expected in 2026. Financial stability is supported by profitability and a near debt-free position.
Puma Biotechnology reports Q4 EPS 26c vs. 39c last year
Reports Q4 revenue $75.5M vs. $59.1M last year. “Our financial performance in the fourth quarter and full year 2025 demonstrates continued momentum, with net income marking our third consecutive year…
Puma Biotechnology sees Q1 revenue $38M-$42M, one estimate $49M
Sees FY26 revenue $214M-$221M, one estimates $220M.
Puma Biotechnology Earnings Call Transcript: Q4 2025
Q4 2025 saw strong revenue growth, with NERLYNX net product revenue and royalties both rising significantly. Clinical trials for alisertib are ahead of schedule, and full-year profitability was achieved for the third consecutive year.
Puma Biotechnology Annual report: Q4 2025
Puma Biotechnology has published its Q4 2025 annual report on February 26, 2026.
Puma Biotechnology Earnings release: Q4 2025
Puma Biotechnology released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Puma Biotechnology Slides: Q4 2025
Puma Biotechnology has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Puma Biotechnology Annual report: Q4 2025
Puma Biotechnology has published its Q4 2025 annual report on February 26, 2026.
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 4Q-2025 earnings release on Feb. 26 and followed with a conference call to review results.
Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO & President Alan Auerbach will provide a corporate overview at the TD Cowen Health Care Conference on March 2 at 2:30 pm ET.
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its fourth quarter and full year 2025 results, followed be a conference call, after the close on Feb. 26, 2026.